Metabolic syndrome in patients with psoriasis, Centro Dermatológico CES Sabaneta, April-June 2012
DOI:
https://doi.org/10.29176/2590843X.288Keywords:
psoriasis, metabolic syndrome, prevalenceAbstract
Background: Psoriasis is a chronic, systemic inflammatory disease, associated with metabolic syndrome and cardiovascular risk, factors that increase the morbidity of patients suffering from it. Prevalence of the metabolic syndrome in the general population varies between 15 and 20%, and in the case of patients with psoriasis it can increase up until 39%. Objective: To determine the prevalence of metabolic syndrome in a cohort of patients diagnosed and/or treated for psoriasis who attended the Centro Dermatológico CES Sabaneta between April 1st and June 15th, 2012. Methods: A descriptive study of patients with psoriasis who were seen at least once at the Centro Dermatológico CES Sabaneta, between April 1st and June 15th, 2012, was carried out. Central tendency measure, dispersion and proportions were calculated. Results: Forty six patients with psoriasis were included, 63% of them had a mild psoriasis and 37% had moderate to severe clinical forms. The prevalence of the metabolic syndrome was 56.5%: in patients with mild clinical forms of psoriasis was 62.1%, and 90% in moderate to severe forms. 43.5% of the patients with psoriasis and metabolic syndrome had a normal corporal mass index, 32.64% were overweight, and 19.68% were obese and 4.3% had low weight Conclusion: This study shows that the study population had a high prevalence of metabolic syndrome associated with psoriasis, but mild forms also have an association with it, not only moderate to severe forms such as described in the literature.
Author Biographies
Sol Beatriz Jiménez
Médica dermatóloga; jefe, Servicio de Dermatología, Universidad CES, Medellín, Colombia
Liliana Montoya
Magíster en Epidemiología; docente, Facultad de Medicina, Universidad CES, Medellín, Colombia
Andrés Gaviria
Estudiante de quinto año, Universidad CES, Medellín, Colombia.
Daniel Gómez
Estudiante de quinto año, Universidad CES, Medellín, Colombia.
Laura Morales
Estudiante de quinto año, Universidad CES, Medellín, Colombia.
Pamela Gallego
Médica dermatóloga, Universidad CES, Medellín, Colombia.
Natalia De la Calle
Médica dermatóloga, Universidad CES, Medellín, Colombia.
References
1. Davidovici BB, Sattar N, Prinz JC, Jörg PC, Puig L, Emery P, et al. Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785-96.
2. Lin HW, Wang KH, Lin HC, Lin HC. Increased risk of acute myocardial infarction in patients with psoriasis: A 5-year population-based study in Taiwan. J Am Acad Dermatol. 2011;64:495-501.
3. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: Results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011;147:419-24.
4. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159:895-902.
5. González C, Londoño A, Castro L. Guías basadas en la evidencia para el manejo de la psoriasis en Colombia. Bogotá: Panamericana Formas e Impresos; 2012.
6. Zindanci I, Albayrak O, Kavala M, Kocaturk E, Can B, Sudogan S, et al. Prevalence of metabolic syndrome in patients with psoriasis. Scientific World Journal. 2012;2012:312463.
7. Shelling ML, Federman DG, Prodanovich S, Kirsner RS. Psoriasis and vascular disease: An unsolved mystery. Am J Med. 2008;121:360-5.
8. El-Mongy S, Fathy H, Abdelaziz A, Omran E, George S, Neseem N, et al. Subclinical atherosclerosis in patients with chronic psoriasis: A potential association. J Eur Acad Dermatol Venereol. 2010;24:661-6.
9. Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol. 2012;39:212-8.
10. Vélez N, Bohórquez L, Corrales MF, Orrego S, Jiménez SB, Zuluaga A, Ochoa FL. Caracterización de los pacientes con psoriasis en tratamiento con fototerapia. Rev Asoc Colomb Dermatol. 2011;19:100-6.
11. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J Off J Jpn Circ Soc. 2004;68:975-81.
12. Fu LW, Vender R. Systemic role for vitamin D in the treatment of psoriasis and metabolic syndrome. Dermatol Res Pract. 2011;2011:276079.
13. Hulthe J, Hultén LM, Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: Atherosclerosis and insulin resistance study. Metabolism. 2003;52:1612-4.
14. Ghazizadeh R, Tosa M, Ghazizadeh M. Clinical improvement in psoriasis with treatment of associated hyperlipidemia. Am J Med Sci. 2011;341:394-8.
15. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;9468:1415-28.
16. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther. 2010;23:137-43.
17. Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and dyslipidaemia: A population-based study. Acta Derm Venereol. 2008;88:561-5.
18. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90:147-51.
19. Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci. 2010;7:284-9.
20. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: Epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20:416-22.
21. Kimball AB, Guérin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25:157-63.
22. Barona MI, Escobar CE. Psoriasis y parapsoriasis En: Falabella R, Victoria J, Barona MI, Domínguez L. Fundamentos de Medicina Dermatológica. Séptima edición. Medellín: Corporación para Investigaciones Biológicas; 2009. p. 64-9.
23. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124:775.e1-6.
24. Londoño A, González C, Castro L, Puig Ll. Psoriasis y su relación con el síndrome metabólico. Rev Colomb Reumatol. 2013;20:228-36.
25. Rosas J, González A, Aschner P, Bastarrachea B. Epidemiología, diagnóstico, control, prevención y tratamiento del síndrome metabólico en adultos. Consensos ALAD. 2010;18:25-44.
26. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol. 2007;157:68-73.
27. Rojas R, Castellanos H, Peñaranda E. Prevalencia del síndrome metabólico, gravedad clínica y calidad de vida en pacientes con psoriasis del Hospital Universitario de La Samaritana. Rev Asoc Colomb Dermatol. 2013;21:220-5.
28. Reyes MA, Paternina H, Garzón H. Guías síndrome metabólico. Primera edición. Bogotá: Thomson PLM, S.A.; 2009. p. 234-47.
29. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-41.
30. Wakkee M, Thio HB, Prens EP, Sijbrands EJG, Neumann HAM. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190:1-9.
31. Martyn-Simmons CL, Ranawaka RR, Chowienczyk P, Crook MA, Marber MS, Smith CH, et al. A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. Br J Dermatol. 2011;164:26-32.
32. Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatol Basel Switz. 2008;217:365-73.
33. Hossler EW, Maroon MS, Mowad CM. Gastric bypass surgery improves psoriasis. J Am Acad Dermatol. 2011;65:198-200.
34. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141:1527-34.
35. Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat ADC. 2010;18:297-304.
36. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med. 2007;167:1670-5.
37. Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI, et al. Obesity in psoriasis: Leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol. 2008;159:342-50.
38. Cakmak SK, Gül U, Kiliç C, Gönül M, Soylu S, Kiliç A. Homocysteine, vitamin B12 and folic acid levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2009;23:300-3.
39. Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25:529-34.
40. Regidor E, Gutiérrez-Fisac JL, Banegas JR, Domínguez V, Rodríguez-Artalejo F. Influencia a lo largo de la vida de las circunstancias socioeconómicas, de la inactividad física y de la obesidad sobre la presencia de síndrome metabólico. Rev Esp Salud Pública. 2007;81:25-31.
41. McDonald I, Connolly M, Tobin AM. A review of psoriasis, a known risk factor for cardiovascular disease and its impact on folate and homocysteine metabolism. J Nutr Metab. 2012;2012:965385.
42. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19:225-30.
43. Singh G, Aneja SPS. Cardiovascular comorbiditiy in psoriasis. Indian J Dermatol. 2011;56:553-6.
44. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treat. 2008;19:5-21.
45. Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, et al. Psoriasis and diabetes: A population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22:585-9.
2. Lin HW, Wang KH, Lin HC, Lin HC. Increased risk of acute myocardial infarction in patients with psoriasis: A 5-year population-based study in Taiwan. J Am Acad Dermatol. 2011;64:495-501.
3. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: Results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011;147:419-24.
4. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159:895-902.
5. González C, Londoño A, Castro L. Guías basadas en la evidencia para el manejo de la psoriasis en Colombia. Bogotá: Panamericana Formas e Impresos; 2012.
6. Zindanci I, Albayrak O, Kavala M, Kocaturk E, Can B, Sudogan S, et al. Prevalence of metabolic syndrome in patients with psoriasis. Scientific World Journal. 2012;2012:312463.
7. Shelling ML, Federman DG, Prodanovich S, Kirsner RS. Psoriasis and vascular disease: An unsolved mystery. Am J Med. 2008;121:360-5.
8. El-Mongy S, Fathy H, Abdelaziz A, Omran E, George S, Neseem N, et al. Subclinical atherosclerosis in patients with chronic psoriasis: A potential association. J Eur Acad Dermatol Venereol. 2010;24:661-6.
9. Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol. 2012;39:212-8.
10. Vélez N, Bohórquez L, Corrales MF, Orrego S, Jiménez SB, Zuluaga A, Ochoa FL. Caracterización de los pacientes con psoriasis en tratamiento con fototerapia. Rev Asoc Colomb Dermatol. 2011;19:100-6.
11. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J Off J Jpn Circ Soc. 2004;68:975-81.
12. Fu LW, Vender R. Systemic role for vitamin D in the treatment of psoriasis and metabolic syndrome. Dermatol Res Pract. 2011;2011:276079.
13. Hulthe J, Hultén LM, Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: Atherosclerosis and insulin resistance study. Metabolism. 2003;52:1612-4.
14. Ghazizadeh R, Tosa M, Ghazizadeh M. Clinical improvement in psoriasis with treatment of associated hyperlipidemia. Am J Med Sci. 2011;341:394-8.
15. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;9468:1415-28.
16. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther. 2010;23:137-43.
17. Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and dyslipidaemia: A population-based study. Acta Derm Venereol. 2008;88:561-5.
18. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90:147-51.
19. Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci. 2010;7:284-9.
20. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: Epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20:416-22.
21. Kimball AB, Guérin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25:157-63.
22. Barona MI, Escobar CE. Psoriasis y parapsoriasis En: Falabella R, Victoria J, Barona MI, Domínguez L. Fundamentos de Medicina Dermatológica. Séptima edición. Medellín: Corporación para Investigaciones Biológicas; 2009. p. 64-9.
23. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124:775.e1-6.
24. Londoño A, González C, Castro L, Puig Ll. Psoriasis y su relación con el síndrome metabólico. Rev Colomb Reumatol. 2013;20:228-36.
25. Rosas J, González A, Aschner P, Bastarrachea B. Epidemiología, diagnóstico, control, prevención y tratamiento del síndrome metabólico en adultos. Consensos ALAD. 2010;18:25-44.
26. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol. 2007;157:68-73.
27. Rojas R, Castellanos H, Peñaranda E. Prevalencia del síndrome metabólico, gravedad clínica y calidad de vida en pacientes con psoriasis del Hospital Universitario de La Samaritana. Rev Asoc Colomb Dermatol. 2013;21:220-5.
28. Reyes MA, Paternina H, Garzón H. Guías síndrome metabólico. Primera edición. Bogotá: Thomson PLM, S.A.; 2009. p. 234-47.
29. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-41.
30. Wakkee M, Thio HB, Prens EP, Sijbrands EJG, Neumann HAM. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190:1-9.
31. Martyn-Simmons CL, Ranawaka RR, Chowienczyk P, Crook MA, Marber MS, Smith CH, et al. A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. Br J Dermatol. 2011;164:26-32.
32. Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatol Basel Switz. 2008;217:365-73.
33. Hossler EW, Maroon MS, Mowad CM. Gastric bypass surgery improves psoriasis. J Am Acad Dermatol. 2011;65:198-200.
34. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141:1527-34.
35. Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat ADC. 2010;18:297-304.
36. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med. 2007;167:1670-5.
37. Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI, et al. Obesity in psoriasis: Leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol. 2008;159:342-50.
38. Cakmak SK, Gül U, Kiliç C, Gönül M, Soylu S, Kiliç A. Homocysteine, vitamin B12 and folic acid levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2009;23:300-3.
39. Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25:529-34.
40. Regidor E, Gutiérrez-Fisac JL, Banegas JR, Domínguez V, Rodríguez-Artalejo F. Influencia a lo largo de la vida de las circunstancias socioeconómicas, de la inactividad física y de la obesidad sobre la presencia de síndrome metabólico. Rev Esp Salud Pública. 2007;81:25-31.
41. McDonald I, Connolly M, Tobin AM. A review of psoriasis, a known risk factor for cardiovascular disease and its impact on folate and homocysteine metabolism. J Nutr Metab. 2012;2012:965385.
42. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19:225-30.
43. Singh G, Aneja SPS. Cardiovascular comorbiditiy in psoriasis. Indian J Dermatol. 2011;56:553-6.
44. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treat. 2008;19:5-21.
45. Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, et al. Psoriasis and diabetes: A population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22:585-9.
How to Cite
1.
Jiménez SB, Montoya L, Gaviria A, Gómez D, Morales L, Gallego P, et al. Metabolic syndrome in patients with psoriasis, Centro Dermatológico CES Sabaneta, April-June 2012. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2015 Jan. 1 [cited 2024 Jul. 3];23(1):30-8. Available from: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/288
Downloads
Download data is not yet available.
Downloads
Published
2015-01-01
How to Cite
1.
Jiménez SB, Montoya L, Gaviria A, Gómez D, Morales L, Gallego P, et al. Metabolic syndrome in patients with psoriasis, Centro Dermatológico CES Sabaneta, April-June 2012. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2015 Jan. 1 [cited 2024 Jul. 3];23(1):30-8. Available from: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/288
Issue
Section
Research Article
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
